Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation

We investigated the effects of disease progression on brain regional neurochemistry in a mutant mouse model of familial amyotrophic lateral sclerosis (FALS; the G93A model) using in vivo and in vitro magnetic resonance spectroscopy (MRS). There were numerous changes in the brain spectra that were brain region dependent. At early time points starting around 80 days of age there were increases in brain glutamate. At later time points there were more extensive changes including decreased N‐acetyl aspartate and glutamate and increased glutamine, taurine and myo‐inositol. The effects of the disease were most severe in spinal cord followed by medulla and then sensorimotor cortex. There were no changes noted in cerebellum as a control region. The effects of creatine supplementation in the diet (2%) were measured in wild‐type and FALS animals in medulla, cerebellum and cortex. The increase in brain creatine was largest in cerebellum (25%) followed by medulla (11%) and then cortex (4%), reflecting the ordering of creatine kinase activity. There was a protective effect of creatine on N‐acetyl aspartate loss in the medulla at late stages. Creatine supplementation had a positive effect on weight retention, leading to a 13% increase in weight between 120 and 130 days. MRS shows promise in monitoring multiple facets of neuroprotective strategies in ALS and ALS models.

[1]  M. Beal,et al.  Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases , 2008, NeuroMolecular Medicine.

[2]  K. Talbot,et al.  Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS , 2008, Progress in Neurobiology.

[3]  J. Lou,et al.  Creatine monohydrate in ALS: Effects on strength, fatigue, respiratory status and ALSFRS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[4]  J. E. Kranz,et al.  Design, power, and interpretation of studies in the standard murine model of ALS , 2008, Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases.

[5]  Christopher Clark,et al.  Disease-modifying therapies for Alzheimer disease , 2007, Neurology.

[6]  Ji-Kyung Choi,et al.  Application of MRS to mouse models of neurodegenerative illness , 2007, NMR in biomedicine.

[7]  Rolf Gruetter,et al.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo1H NMR spectroscopy , 2007, Journal of neurochemistry.

[8]  H. Heinze,et al.  Metabolic progression markers of neurodegeneration in the transgenic G93A‐SOD1 mouse model of amyotrophic lateral sclerosis , 2007, The European journal of neuroscience.

[9]  M. F. Beal,et al.  Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG , 2006, Neurology.

[10]  Elaine Holmes,et al.  Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. , 2006, Journal of proteome research.

[11]  O. Andreassen,et al.  Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease , 2005, Journal of neurochemistry.

[12]  J. Neale,et al.  The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. , 2005, Trends in pharmacological sciences.

[13]  Clifford R Jack,et al.  Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Bradford C. Dickerson,et al.  Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer’s disease , 2005, NeuroRX.

[15]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[16]  T. Conrad,et al.  A clinical trial of creatine in ALS , 2004, Neurology.

[17]  Sanjay Kalra,et al.  ALS surrogate markers. MRS. , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[18]  Ji-Kyung Choi,et al.  Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile , 2004, Brain Research.

[19]  M. Tarnopolsky,et al.  Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice , 2003, Neuroscience.

[20]  Joseph A. Helpern,et al.  In Vivo NMR Studies of Neurodegenerative Diseases in Transgenic and Rodent Models , 2003, Neurochemical Research.

[21]  J. Veldink,et al.  A randomized sequential trial of creatine in amyotrophic lateral sclerosis , 2003, Annals of neurology.

[22]  David H. Miller.  MRI monitoring of MS in clinical trials , 2002, Clinical Neurology and Neurosurgery.

[23]  C. Elger,et al.  Effect of Creatine Supplementation on Metabolite Levels in ALS Motor Cortices , 2001, Experimental Neurology.

[24]  R. Gruetter,et al.  Metabolic changes in quinolinic acid‐lesioned rat striatum detected non‐invasively by in vivo 1H NMR spectroscopy , 2001, Journal of neuroscience research.

[25]  O. Andreassen,et al.  Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation , 2001, Journal of neurochemistry.

[26]  V. Eraković,et al.  Altered Activities of Rat Brain Metabolic Enzymes in Electroconvulsive Shock—Induced Seizures , 2001, Epilepsia.

[27]  O. Andreassen,et al.  Nonlinear Decrease over Time in N‐Acetyl Aspartate Levels in the Absence of Neuronal Loss and Increases in Glutamine and Glucose in Transgenic Huntington's Disease Mice , 2000, Journal of neurochemistry.

[28]  T. Ng,et al.  1H-MRS evidence of neurodegeneration and excess glutamate glutamine in ALS medulla , 1999, Neurology.

[29]  D. Arnold,et al.  Biological markers in the diagnosis and treatment of ALS , 1999, Journal of the Neurological Sciences.

[30]  Ole A. Andreassen,et al.  Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis , 1999, Nature Medicine.

[31]  D. Borchelt,et al.  ALS-Linked SOD1 Mutant G85R Mediates Damage to Astrocytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions , 1997, Neuron.

[32]  A. Levey,et al.  Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis , 1995, Annals of neurology.

[33]  A. Plaitakis,et al.  Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartylglutamate in amyotrophic lateral sclerosis , 1993, Brain Research Bulletin.

[34]  J. Coyle,et al.  Abnormal acidic amino acids and N-acetylaspartylglutamate in hereditary canine motoneuron disease , 1993, Brain Research.

[35]  Jeffrey D. Rothstein,et al.  Reductions in acidic amino acids andN-acetylaspartylglutamate in amyotrophic lateral sclerosis CNS , 1991, Brain Research.

[36]  Anthony Traboulsee,et al.  The use of MRI as an outcome measure in clinical trials. , 2006, Advances in neurology.